Eli Lilly shares rose 7.18% in pre-market trading on February 4, 2026. The stock reached a price of $1075.49. This follows a close of $1003.46 on February 3. The previous session ended with a 3.90% decline.
The company reports Q4 and full-year 2025 earnings before the market opens. Consensus estimates forecast an EPS of $6.99. This projection represents a 31.39% year-over-year increase.
Investor anticipation centers on tirzepatide-driven results. The pre-market gain outpaces S&P 500 futures, which rose 0.14%. This upward movement occurs despite recent volatility and a 15% drop in competitor Novo Nordisk.